Hartford Financial Management Inc. Adverum Biotechnologies, Inc. Transaction History

Hartford Financial Management Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 10, 2018	SELL	$5.3 - $6.9 $23,850 - $31,050	-4,500 Closed	0 $0
Q1 2018 Apr 10, 2018	BUY	$3.65 - $7.95 $9,125 - $19,875	2,500 Added 125.0%	4,500 $26,000
Q4 2017 Jan 16, 2018	BUY	$2.85 - $3.95 $5,700 - $7,900	2,000	2,000 $7,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Hartford Financial Management Inc., based on Form 13F filings with the SEC.

Stay updated on Hartford Financial Management Inc. with notifications on news.